Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNC101 in Metastatic Colorectal Cancer
NCT02726334Phase 1Terminated
- Sponsor
- Neuphoria Therapeutics Inc.
- Start
- Mar 2016
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of bnc101 in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Neuphoria Therapeutics Inc. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Mar 2016; status: terminated.
02
Drugs
bnc101
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02726334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02726334.